Literature DB >> 1955119

Activation and signaling status of human lamina propria T lymphocytes.

L Qiao1, G Schürmann, M Betzler, S C Meuer.   

Abstract

In this study, proliferative responses of human lamina propria T lymphocytes were examined in vitro. The response of lamina propria T lymphocytes to Sepharose-bound anti-CD3 antibody plus interleukin 2 was significantly lower than the response of autologous peripheral blood T lymphocytes, whereas the responses of lamina propria T lymphocytes to anti-T11(2/3) antibodies plus sheep erythrocytes or anti-CD28 antibody plus interleukin 2 were largely preserved. After coculture with mucosa supernatant, peripheral blood T lymphocytes showed a similar pattern of reactivity as lamina propria T lymphocytes. This reduced reactivity to T-cell antigen receptor stimulation appears to exist at the level of signal transduction, because triggering of CD3 induces low amounts of intracellular inositol 1,4,5-triphosphate and no free calcium increase in lamina propria T lymphocytes when compared with peripheral blood T lymphocytes. This study indicates that the antigen receptor-dependent activation pathway of lamina propria T lymphocytes for proliferation is down-regulated by intestinal mucosa derived factor(s) and that the alternative pathways mediated by CD2 or CD28 are largely preserved. Based on previous data that lamina propria T lymphocytes can provide help to B cells, it is possible that these alternative activation pathways play an important role in T-B cell interaction in the gut.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955119     DOI: 10.1016/0016-5085(91)90388-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

3.  Binding of intimin from enteropathogenic Escherichia coli to lymphocytes and its functional consequences.

Authors:  Nathalie S Gonçalves; Christine Hale; Gordon Dougan; Gad Frankel; Thomas T MacDonald
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 4.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

5.  Comparative studies of superoxide production by microbial wall product-primed neutrophils in ulcerative colitis.

Authors:  Sara Elsøe Nielsen; Ben Vainer; Ole Haagen Nielsen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 6.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

7.  Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro.

Authors:  Claudia Guzy; Anja Schirbel; Daniela Paclik; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  Eur J Nutr       Date:  2008-11-08       Impact factor: 5.614

8.  Interleukin-7 activates intestinal lymphocytes.

Authors:  M Bilenker; A I Roberts; R E Brolin; E C Ebert
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis.

Authors:  A Stallmach; F Schäfer; S Hoffmann; S Weber; I Müller-Molaian; T Schneider; G Köhne; K W Ecker; G Feifel; M Zeitz
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.